异基因干细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性大B细胞淋巴瘤 - Suppr

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

作者信息

Lutfi Forat, Holtzman Noa, Siglin Jonathan, Bukhari Ali, Mustafa Ali Moaath, Kim Dong, Sanchez-Petitto Gabriela, Gottlieb David, Ruehle Kathleen, Hutnick Elizabeth, Gahres Natalie, Hankey Kim, Lee Seung, Kocoglu Mehmet, Yared Jean, Hardy Nancy, Rapoport Aaron, Dahiya Saurabh

机构信息

Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA.

Medicine, University of Maryland Medical Center, Baltimore, MD, USA.

出版信息

Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10.

DOI:10.1111/bjh.17121

PMID:33169845

Abstract

摘要

相似文献

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.异基因干细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性大B细胞淋巴瘤

Br J Haematol. 2021 Jan;192(1):212-216. doi: 10.1111/bjh.17121. Epub 2020 Nov 10.

Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。

Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.

Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.滤泡性淋巴瘤的细胞治疗：自体造血干细胞移植、异基因造血干细胞移植和嵌合抗原受体 T 细胞治疗。

Hematol Oncol Clin North Am. 2020 Aug;34(4):701-714. doi: 10.1016/j.hoc.2020.02.006. Epub 2020 Apr 16.

Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort.免疫治疗后复发/难治性非霍奇金淋巴瘤的异基因移植：与历史队列的比较。

Cytotherapy. 2024 Oct;26(10):1163-1169. doi: 10.1016/j.jcyt.2024.05.002. Epub 2024 May 5.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.异基因造血细胞移植后嵌合抗原受体T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤的安全性和可行性

Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.

Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.嵌合抗原受体 T 细胞在异基因造血干细胞移植中的应用。

Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.

Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.异基因造血干细胞移植和嵌合抗原受体（CAR）T 细胞治疗非霍奇金淋巴瘤。

Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.

Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation.异基因干细胞移植后患者中，替沙格赛基因导致的移植物抗宿主病

Br J Haematol. 2021 Dec;195(5):805-811. doi: 10.1111/bjh.17737. Epub 2021 Jul 28.

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?异基因移植在淋巴瘤治疗中仍有作用吗？

J Clin Oncol. 2021 Feb 10;39(5):487-498. doi: 10.1200/JCO.20.01447. Epub 2021 Jan 12.

Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.供体来源的靶向CD19的T细胞输注可诱导复发的B细胞急性淋巴细胞白血病患者达到微小残留病阴性缓解，这些患者在单倍体造血干细胞移植后对供体淋巴细胞输注无反应。

Br J Haematol. 2017 Nov;179(4):598-605. doi: 10.1111/bjh.14923. Epub 2017 Oct 26.

引用本文的文献

Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.一名转化型滤泡性淋巴瘤患者在异基因干细胞移植后复发，接受CAR-T治疗后长期缓解。

Ann Hematol. 2025 Jan;104(1):841-845. doi: 10.1007/s00277-024-06150-8. Epub 2024 Dec 30.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.异基因造血细胞移植后抗CD19嵌合抗原受体T细胞治疗后的移植物抗宿主病：移植并发症和儿科疾病工作组的欧洲血液与骨髓移植协会联合研究

Leukemia. 2025 Feb;39(2):431-437. doi: 10.1038/s41375-024-02467-5. Epub 2024 Nov 19.

Sclerotic chronic cutaneous graft-versus-host-disease following pseudoallogeneic chimeric antigen receptor T-cell therapy.假性同种异体嵌合抗原受体T细胞治疗后发生的硬化性慢性皮肤移植物抗宿主病。

JAAD Case Rep. 2024 Jul 6;52:42-45. doi: 10.1016/j.jdcr.2024.06.014. eCollection 2024 Oct.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.下一代靶向BCMA的嵌合抗原受体CARTemis-1：生产工艺对CAR T细胞特性的影响

Cell Oncol (Dordr). 2025 Feb;48(1):219-237. doi: 10.1007/s13402-024-00984-0. Epub 2024 Aug 27.

PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.PD-1 检查点抑制增强了保留预防同种异体反应能力的 CD19-CAR-iNKT 细胞的抗淋巴瘤活性。

J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829.

Allogeneic hematopoietic stem cell transplantation for B-cell lymphoma in Taiwan.台湾地区 B 细胞淋巴瘤的异基因造血干细胞移植。

Cancer Med. 2023 Dec;12(24):21761-21769. doi: 10.1002/cam4.6741. Epub 2023 Nov 28.

Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后免疫检查点抑制剂的安全性和疗效。

Bone Marrow Transplant. 2023 Oct;58(10):1075-1083. doi: 10.1038/s41409-023-02073-6. Epub 2023 Jul 29.

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.CD19+ 谱系嵌合体，是先前接受过造血干细胞移植的患者接受抗 CD19 CAR-T 细胞治疗后的早期生物标志物。

Front Immunol. 2022 Aug 8;13:960412. doi: 10.3389/fimmu.2022.960412. eCollection 2022.

Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.CD19嵌合抗原受体T细胞疗法治疗异基因造血干细胞移植后复发的急性淋巴细胞白血病患者的疗效与安全性。

Int J Hematol. 2022 Sep;116(3):315-329. doi: 10.1007/s12185-022-03398-6. Epub 2022 Jun 23.

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.定制 CARs：利用同种异体 CAR 疗法的适应性解决复发/难治性弥漫性大 B 细胞淋巴瘤中的当前挑战。

Front Immunol. 2022 May 18;13:887866. doi: 10.3389/fimmu.2022.887866. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献